Cancer immunotherapy

Results: 490



#Item
1# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

Add to Reading List

Source URL: www.biolinerx.com

Language: English - Date: 2017-03-27 02:02:40
    2Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

    Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

    Add to Reading List

    Source URL: www.proimmune.com

    Language: English - Date: 2016-06-13 06:09:49
      3FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

      FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

      Add to Reading List

      Source URL: cancer.ucsf.edu

      - Date: 2016-11-10 15:08:46
        4Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

        Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

        Add to Reading List

        Source URL: www.rubinsteyn.com

        - Date: 2017-03-28 12:28:33
          5JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis

          JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis

          Add to Reading List

          Source URL: www.parkerici.org

          - Date: 2016-12-09 15:56:02
            6VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

            VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

            Add to Reading List

            Source URL: sunstone.eu

            Language: English - Date: 2016-07-12 04:22:18
            7Cover Conference-at-a-Glance Final Agenda Eighth Annual

            Cover Conference-at-a-Glance Final Agenda Eighth Annual

            Add to Reading List

            Source URL: www.giievent.jp

            Language: English - Date: 2016-08-16 03:53:14
            8F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

            F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

            Add to Reading List

            Source URL: www.f-star.com

            Language: English - Date: 2016-07-13 10:00:22
            917427_UKW_AG-Bumm_Postdoc.cdr

            17427_UKW_AG-Bumm_Postdoc.cdr

            Add to Reading List

            Source URL: www.labtimes.org

            Language: English - Date: 2016-08-05 06:11:11